iSpecimen (iSpecimen) 3-Year Revenue Growth Rate

: -17.10% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

iSpecimen's Revenue per Share for the three months ended in Dec. 2023 was $0.28.

During the past 12 months, iSpecimen's average Revenue per Share Growth Rate was -6.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -17.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 6 years, the highest 3-Year average Revenue per Share Growth Rate of iSpecimen was 35.80% per year. The lowest was -17.10% per year. And the median was 21.10% per year.

Competitive Comparison

For the Diagnostics & Research subindustry, iSpecimen's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iSpecimen 3-Year Revenue Growth Rate Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where iSpecimen's 3-Year Revenue Growth Rate falls into.

iSpecimen 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

iSpecimen (NAS:ISPC) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

iSpecimen 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of iSpecimen's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

iSpecimen (iSpecimen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 Bedford Street, Lexington, MA, USA, 02420

Website

https://www.ispecimen.com

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

Executives

Benjamin Bielak	officer: Chief Information Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley	officer: Chief Financial Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile	director	450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross	director, 10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d.	director	C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc	10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence	director	450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl	director	450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli	director, officer: CEO, President	450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan	director, officer: COO, Secretary, Treasurer	450 BEDFORD STREET, LEXINGTON MA 02420